Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence

Stem Cell Research & Therapy

Johannes Paede¹  Johann Pfeifer²  Eva Margreiter²  Andrea Frudinger³  Marco Thurner⁴  Rainer Marksteiner⁴ 

[1] B-K Ultrasound;Department of General Surgery, Medical University of Graz;Department of Obstetrics and Gynaecology, Division of Gynaecology, Medical University of Graz;Innovacell Biotechnologie AG;

关键词: Faecal incontinence;    Anal sphincter;    Cell therapy;    Autologous skeletal muscle derived cells;   

DOI  :  10.1186/s13287-018-0978-y

来源: DOAJ

【 摘 要 】

Abstract Background In an earlier pilot study with 10 women, we investigated a new approach for therapy of faecal incontinence (FI) due to obstetric trauma, involving ultrasound-guided injection of autologous skeletal muscle-derived cells (SMDC) into the external anal sphincter (EAS), and observed significant improvement. In the current study, we tested this therapeutic approach in an extended patient group: male and female patients suffering from FI due to EAS damage and/or atrophy. Furthermore, feasibility of lower cell counts and cryo-preserved SMDC was assessed. Methods In this single-centre, explorative, baseline-controlled clinical trial, each patient (n = 39; mean age 60.6 ± 13.81 years) received 79.4 ± 22.5 × 106 cryo-preserved autologous SMDC. Changes in FI parameters, Fecal Incontinence Quality of Life (FIQL), anorectal manometry and safety from baseline to 1, 6 and 12 months post implantation were evaluated. Results SMDC used in this trial contained a high percentage of myogenic-expressing (CD56+) and muscle stem cell marker-expressing (Pax7+, Myf5+) cells. Intervention was well tolerated without any serious adverse events. After 12 months, the number of weekly incontinence episodes (WIE, primary variable), FIQL and patient condition had improved significantly. In 80.6% of males and 78.4% of females, the WIE frequency decreased by at least 50%; Wexner scores and severity of FI complaints decreased significantly, independent of gender and cause of FI. Conclusions Injection of SMDCs into the EAS effectively improved sphincter-related FI due to EAS damage and/or atrophy in males and females. When confirmed in a larger, placebo-controlled trial, this minimal invasive procedure has the potential to become first-line therapy for FI. Trial registration EU Clinical Trials Register, EudraCT 2010-023826-19 (Date of registration: 08.11.2010).

【 授权许可】

Unknown